Page last updated: 2024-10-21

phenytoin and Psychoses, Drug

phenytoin has been researched along with Psychoses, Drug in 32 studies

Research Excerpts

ExcerptRelevanceReference
" The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described."3.72Acute psychosis due to treatment with phenytoin in a nonepileptic patient. ( Angelopoulos, E; Gatzonis, SD; Mantouvalos, V; Ploumbidis, D; Sarigiannis, P; Siafakas, A, 2003)
"A 21-year-old white man, with propionic acidemia and seizures treated with phenytoin and carbamazepine, was started on isradipine for essential hypertension."3.71Phenytoin/isradipine interaction causing severe neurologic toxicity. ( Cachat, F; Tufro, A, 2002)
"Decreased libido and impotence were more common in patients given primidone."2.66Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. ( Browne, TR; Collins, JF; Cramer, JA; Delgado-Escueta, AV; Mattson, RH; McCutchen, CB; McNamara, JO; Smith, DB; Treiman, DM; Williamson, PD, 1985)
"32 patients with Sydenham's chorea were studied at the La Rabida Institute for psychometric performance on the Minnesota Multiphasic Personality Inventory (MMPI)."1.27Chronic dopaminergic sensitivity after Sydenham's chorea. ( Bacon, LD; Bieliauskas, LA; Glantz, RN; Hagerty, M; Koller, WC; Nausieda, PA, 1983)

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-199025 (78.13)18.7374
1990's3 (9.38)18.2507
2000's3 (9.38)29.6817
2010's1 (3.13)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shimura, M1
Yamada, H1
Takahashi, H1
Yamada, N1
Go, S1
Yamanaka, G1
Kawashima, H1
Cachat, F1
Tufro, A1
MOLING, JH1
POSCH, JJ1
Gatzonis, SD1
Angelopoulos, E1
Sarigiannis, P1
Mantouvalos, V1
Ploumbidis, D1
Siafakas, A1
Cvetko, B1
Dahl, JR1
Nausieda, PA1
Bieliauskas, LA1
Bacon, LD1
Hagerty, M1
Koller, WC1
Glantz, RN1
Reynolds, EH2
Surman, OS1
Parker, SW1
Tsuji, M1
Hori, S1
Asai, N1
Hamanaka, T1
Ishikawa, T1
Hiyoshi, T1
Mochizuki, H1
Kanemoto, K1
Miyamoto, T1
Kawasaki, J1
Freed, ED1
Stores, G1
Franks, RD1
Richter, AJ1
Gill, MA1
Kern, JW1
Kaneko, J1
McKeon, J1
Davis, C1
Trimble, MR1
Efabumuyi, OI1
Jefries, JJ1
Herberg, KP1
McDanal, CE1
Bolman, WM1
Mark, VH1
Zbinden, G1
Sultan, S1
Chouinard, G1
Beaudry, P1
Kugoh, T1
Inoue, T1
Utsumi, T1
Hamada, T1
Hosokawa, K1
Lepore, V1
Di Reda, N1
Defazio, G1
Pedone, D1
Giovine, A1
Lanzi, C1
Tartaglione, B1
Livrea, P1
Miller, WI1
Bhatia, MS1
Singhal, PK1
Kaur, N1
Gallitto, G1
Bramanti, P1
Di Rosa, AE1
Musolino, R1
De Domenico, P1
Troilo, G1
Santoro, M1
Di Perri, R1
Mattson, RH1
Cramer, JA1
Collins, JF1
Smith, DB1
Delgado-Escueta, AV1
Browne, TR1
Williamson, PD1
Treiman, DM1
McNamara, JO1
McCutchen, CB1
Gibberd, FB1
Fahn, S1
Craddock, G1
Kumin, G1
Andreasen, PB1
Heshe, J1
Patel, H1
Crichton, JU1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418]Phase 4122 participants (Actual)Interventional2006-02-28Terminated (stopped due to Insufficient enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Adverse Event Profile (AEP) Score

Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months

InterventionUnits on a scale (Mean)
VNS Therapy-6.0
Best Medical Practice-3.2

Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Score

The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months

InterventionUnits on a Scale (Mean)
VNS Therapy-2.2
Best Medical Practice0.5

Change From Baseline in Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) Score

The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months

InterventionUnits on a Scale (Mean)
VNS Therapy-1.0
Best Medical Practice-0.2

Changes in Anti-epileptic Drugs (AEDs)

Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months

InterventionNumber of AEDs Taken (Median)
VNS Therapy0
Best Medical Practice0

Mean Change From Beginning of Intervention Clinical Global Impression-Improvement Scale (CGI-I) Score at 12 Months

The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months

InterventionUnits on a Scale (Mean)
VNS Therapy-0.8
Best Medical Practice-0.3

Mean Percent Change in Seizure Frequency

Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months

InterventionPercent Change (Mean)
VNS Therapy-19.1
Best Medical Practice-1.0

Overall Quality of Life in Epilepsy-89 (QOLIE-89) Score in Patients With Baseline & at Least One Post-baseline QOLIE Assessment

QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months

Interventionunits on a scale (Mean)
VNS Therapy5.5
Best Medical Practice1.2

Response Rate

Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months

Interventionparticipants (Number)
VNS Therapy10
Best Medical Practice7

Change From Baseline in QOLIE-89 Measures: Subgroup Analysis of Population With Baseline Adverse Event Profile Score < 40

QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months

Interventionunits on a scale (Least Squares Mean)
VNS TherapyBest Medical Practice
Baseline Adverse Event Profile Score < 403.30.5

Change From Baseline in QOLIE-89 Measures: Subgroup Analysis of Population With Baseline Adverse Event Profile Score >= 40

QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months

InterventionUnits on a Scale (Least Squares Mean)
VNS TherapyBest Medical Practice
Baseline Adverse Event Profile Score >= 403.30.7

Reviews

2 reviews available for phenytoin and Psychoses, Drug

ArticleYear
Mental effects of antiepileptic medication: a review.
    Epilepsia, 1983, Volume: 24 Suppl 2

    Topics: Adolescent; Adult; Anticonvulsants; Attention; Barbiturates; Brain Chemistry; Carbamazepine; Child;

1983
Behavioural effects of anti-epileptic drugs.
    Developmental medicine and child neurology, 1975, Volume: 17, Issue:5

    Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Confusion; Disorders of Excess

1975

Trials

1 trial available for phenytoin and Psychoses, Drug

ArticleYear
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.
    The New England journal of medicine, 1985, Jul-18, Volume: 313, Issue:3

    Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Epilepsies, P

1985

Other Studies

29 other studies available for phenytoin and Psychoses, Drug

ArticleYear
Antiepileptic drug-induced psychosis associated with MTHFR C677T: a case report.
    Journal of medical case reports, 2019, Aug-12, Volume: 13, Issue:1

    Topics: Adolescent; Anticonvulsants; Avitaminosis; Epilepsy; Humans; Male; Methylenetetrahydrofolate Reducta

2019
Phenytoin/isradipine interaction causing severe neurologic toxicity.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:9

    Topics: Acidosis; Adult; Anticonvulsants; Antihypertensive Agents; Calcium Channel Blockers; Drug Interactio

2002
Acute diphenylhydantoin intoxication: report of two cases.
    Pediatrics, 1957, Volume: 20, Issue:5, Part 1

    Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydantoins; Phenytoin; Psychoses, Substance

1957
Acute psychosis due to treatment with phenytoin in a nonepileptic patient.
    Epilepsy & behavior : E&B, 2003, Volume: 4, Issue:6

    Topics: Anticonvulsants; Female; Humans; Middle Aged; Phenytoin; Psychoses, Substance-Induced; Trigeminal Ne

2003
[Intolerance syndrome in diphenylhydantoin therapy].
    Neuropsihijatrija, 1966, Volume: 14, Issue:1

    Topics: Cerebellum; Drug Hypersensitivity; Electroencephalography; Humans; Male; Phenytoin; Psychoses, Subst

1966
Diphenylhydantoin toxic psychosis with associated hyperglycemia.
    California medicine, 1967, Volume: 107, Issue:4

    Topics: Glycosuria; Humans; Hyperglycemia; Male; Middle Aged; Phenytoin; Psychoses, Substance-Induced

1967
Chronic dopaminergic sensitivity after Sydenham's chorea.
    Neurology, 1983, Volume: 33, Issue:6

    Topics: Adult; Amphetamines; Appetite Depressants; Chorea; Contraceptives, Oral; Dopamine; Female; Humans; M

1983
Complex partial seizures and psychiatric disturbance in end-stage renal disease.
    Psychosomatics, 1981, Volume: 22, Issue:12

    Topics: Acute Kidney Injury; Adult; Anticonvulsants; Electroencephalography; Female; Humans; Methyldopa; Phe

1981
Two epileptics showing antiepileptic drug-induced psychoses.
    The Japanese journal of psychiatry and neurology, 1993, Volume: 47, Issue:2

    Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroenc

1993
Running down phenomenon and acute interictal psychosis in medial temporal lobe epilepsy.
    Epilepsy research, 2000, Volume: 39, Issue:1

    Topics: Adult; Age Factors; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Humans; Isoxazoles; Male; Phen

2000
The drug management of acute behavioural disturbances.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1975, Apr-05, Volume: 49, Issue:15

    Topics: Acting Out; Acute Disease; Adrenergic beta-Antagonists; Aged; Antidepressive Agents, Tricyclic; Anti

1975
Schizophrenia-like psychosis associated with anticonvulsant toxicity.
    The American journal of psychiatry, 1979, Volume: 136, Issue:7

    Topics: Adult; Anticonvulsants; Athetosis; Carbamazepine; Chorea; Dose-Response Relationship, Drug; Drug The

1979
Phenytoin overdose. Kinetics.
    The Western journal of medicine, 1978, Volume: 128, Issue:3

    Topics: Humans; Kinetics; Male; Middle Aged; Phenytoin; Psychoses, Substance-Induced

1978
Anticonvulsant drugs and mental symptoms: a review.
    Psychological medicine, 1976, Volume: 6, Issue:2

    Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Ethosuximide; Folic Acid

1976
Treatment of drug-induced psychosis with diphenylhydantoin.
    Canadian Psychiatric Association journal, 1976, Volume: 21, Issue:8

    Topics: Adult; Cognition Disorders; Female; Hallucinations; Hallucinogens; Humans; Illusions; Male; Phenytoi

1976
Delayed and insidious onset of diphenylhydantoin toxicity.
    Southern medical journal, 1975, Volume: 68, Issue:1

    Topics: Adolescent; Adult; Animals; Cerebellar Ataxia; Drug Interactions; Electroencephalography; Epilepsy;

1975
Delayed idiosyncratic psychosis with diphenylhydantoin.
    JAMA, 1975, Mar-10, Volume: 231, Issue:10

    Topics: Adult; Epilepsy; Female; Humans; Paranoid Disorders; Phenytoin; Psychoses, Substance-Induced; Time F

1975
Letter: Delayed idiosyncratic psychosis with phenytoin.
    JAMA, 1975, Nov-03, Volume: 234, Issue:5

    Topics: Humans; Phenytoin; Psychoses, Substance-Induced

1975
[Dangers of drug combinations (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1976, Mar-23, Volume: 65, Issue:11

    Topics: Anticoagulants; Barbiturates; Contraceptives, Oral, Hormonal; Drug Antagonism; Drug Interactions; Dr

1976
Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis.
    Progress in neuro-psychopharmacology & biological psychiatry, 1990, Volume: 14, Issue:3

    Topics: Adult; Antipsychotic Agents; Carbamazepine; Female; Humans; Male; Middle Aged; Phenytoin; Psychoses,

1990
Five epileptic cases who manifested psychotic states under the toxic levels of antiepileptic drugs.
    The Japanese journal of psychiatry and neurology, 1990, Volume: 44, Issue:2

    Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy; Humans; Phen

1990
Dopaminomimetic action of diphenylhydantoin in rat striatum: effect on homovanillic acid and cyclic AMP levels.
    Psychopharmacology, 1985, Volume: 86, Issue:1-2

    Topics: Animals; Apomorphine; Corpus Striatum; Cyclic AMP; Dyskinesia, Drug-Induced; Haloperidol; Homovanill

1985
Phenytoin chronic toxicity and associated psychosis.
    Drug intelligence & clinical pharmacy, 1988, Volume: 22, Issue:12

    Topics: Aged; Chronic Disease; Female; Humans; Phenytoin; Psychoses, Substance-Induced

1988
Psychosis associated with anticonvulsant toxicity.
    Indian pediatrics, 1987, Volume: 24, Issue:6

    Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Humans; Intellectual Disability; Male; Phenytoin;

1987
Diphenylhydantoin encephalopathy. A case report.
    Acta neurologica, 1985, Volume: 7, Issue:1

    Topics: Adult; Dose-Response Relationship, Drug; Electroencephalography; Epilepsies, Partial; Evoked Potenti

1985
Epilepsy.
    British medical journal, 1969, Nov-01, Volume: 4, Issue:5678

    Topics: Adult; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, T

1969
Acute toxic psychosis from suicidal overdosage of amantadine.
    Archives of neurology, 1971, Volume: 25, Issue:1

    Topics: Acute Disease; Amantadine; Blood-Brain Barrier; Chlorpromazine; Humans; Male; Middle Aged; Parkinson

1971
[Neuropsychiatric manifestations of systemic lupus erythematosus].
    Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry, 1969, Volume: 23, Issue:5

    Topics: Adult; Chlorpromazine; Chlorprothixene; Female; Humans; Lupus Erythematosus, Systemic; Neurologic Ma

1969
The neurologic hazards of diphenylhydantoin in childhood.
    The Journal of pediatrics, 1968, Volume: 73, Issue:5

    Topics: Adolescent; Ataxia; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Male; Neurologic Mani

1968